Tempus AI (NASDAQ:TEM) Sees Unusually-High Trading Volume – Here’s Why

Shares of Tempus AI, Inc. (NASDAQ:TEM) saw an uptick in trading volume on Tuesday . 12,338,586 shares changed hands during trading, an increase of 5% from the previous session’s volume of 11,781,585 shares.The stock last traded at $74.17 and had previously closed at $68.36.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TEM. Needham & Company LLC restated a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research report on Tuesday, January 14th. TD Cowen restated a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and raised their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Piper Sandler restated a “neutral” rating and set a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Loop Capital cut their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Stock Up 2.2 %

The company has a 50 day moving average price of $44.60 and a 200 day moving average price of $49.36. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Buying and Selling

In other news, CEO Eric P. Lefkofsky sold 80,388 shares of the company’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $67.53, for a total transaction of $5,428,601.64. Following the completion of the transaction, the chief executive officer now directly owns 5,293,005 shares of the company’s stock, valued at $357,436,627.65. This represents a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David R. Epstein sold 620 shares of Tempus AI stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total value of $25,922.20. Following the completion of the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. This represents a 2.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,229,449 shares of company stock valued at $102,293,124 over the last three months.

Institutional Investors Weigh In On Tempus AI

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Horizon Advisors Inc. acquired a new stake in Tempus AI in the 3rd quarter valued at approximately $30,000. Farther Finance Advisors LLC bought a new position in Tempus AI in the fourth quarter valued at approximately $34,000. FNY Investment Advisers LLC bought a new position in Tempus AI in the fourth quarter valued at approximately $67,000. IFP Advisors Inc bought a new position in Tempus AI in the fourth quarter valued at approximately $76,000. Finally, US Bancorp DE bought a new position in Tempus AI in the fourth quarter valued at approximately $80,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.